BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 25797247)

  • 1. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
    Koo J; Yue P; Gal AA; Khuri FR; Sun SY
    Cancer Res; 2014 May; 74(9):2555-68. PubMed ID: 24626091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis.
    Zhang S; Qian G; Zhang QQ; Yao Y; Wang D; Chen ZG; Wang LJ; Chen M; Sun SY
    Cancer Res; 2019 Jul; 79(14):3725-3736. PubMed ID: 31142514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
    Koo J; Wu X; Mao Z; Khuri FR; Sun SY
    J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of GSK3 cellular location by FRAT modulates mTORC1-dependent cell growth and sensitivity to rapamycin.
    He L; Fei DL; Nagiec MJ; Mutvei AP; Lamprakis A; Kim BY; Blenis J
    Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19523-19529. PubMed ID: 31492813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
    Li S; Oh YT; Yue P; Khuri FR; Sun SY
    Oncogene; 2016 Feb; 35(5):642-50. PubMed ID: 25893295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
    Shu L; Houghton PJ
    Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
    Ma Z; Zhu L; Luo X; Zhai S; Li P; Wang X
    Cancer Biol Ther; 2012 Sep; 13(11):1009-17. PubMed ID: 22825337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
    Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
    J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.
    Koo J; Yue P; Deng X; Khuri FR; Sun SY
    Mol Cell Biol; 2015 Jul; 35(13):2344-55. PubMed ID: 25918246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
    Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
    Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.
    Du W; Gerald D; Perruzzi CA; Rodriguez-Waitkus P; Enayati L; Krishnan B; Edmonds J; Hochman ML; Lev DC; Phung TL
    Lab Invest; 2013 Oct; 93(10):1115-27. PubMed ID: 23938603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
    Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
    Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells.
    Hoshii T; Kasada A; Hatakeyama T; Ohtani M; Tadokoro Y; Naka K; Ikenoue T; Ikawa T; Kawamoto H; Fehling HJ; Araki K; Yamamura K; Matsuda S; Hirao A
    Proc Natl Acad Sci U S A; 2014 Mar; 111(10):3805-10. PubMed ID: 24567410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.